25
Single Baseline Characteristics by OS With Nivolumab
CheckMate 057: Nivolumab vs Docetaxel in Previously Treated NSQ NSCLC
Patients with factor in
OS subgroup (%)
OS ≤3 months
OS >3 months
Based on a March 18, 2015 database lock;
a
Percentages of patients are based on numbers of patients with quantifiable PD-L1 expression at baseline; maint. = maintenance;
mets = metastases; mut. = mutation; pos. = positive; resp. = response; TX = treatment
<3 mo
from
last TX
PD
best
resp.
No
maint.
TX
>5 sites
with
lesions
Bone
mets
Liver
mets
Never
Current/
former
0
1
<1%
≥1%
≥5% ≥10%
EGFR
mut.-pos.
Prior
therapy
Smoking
status
Baseline
disease site
PD-L1
expression
a
ECOG
PS
• Post-hoc, exploratory multivariate analysis suggested that nivolumab-treated patients with poorer prognostic features and/or
aggressive disease when combined with lower or no tumor PD-L1 expression may be at higher risk of death within the first
3 months
– These included the following known prognostic factors: <3 months since last treatment, PD as best response to prior treatment, and
ECOG PS = 1
